iBio Establishes New $100M At-The-Market Offering Program, Terminating Prior Smaller Facility
IBIO has more than doubled off its 52-week low of $0.556 on light trading volume (0.2× avg).
Summary
iBio, Inc. entered into a new At-The-Market (ATM) offering agreement with Jefferies LLC to sell up to $100 million of common stock, replacing a smaller, prior ATM program.
Key Events · Financing and Capital Events · IBIO
-
New $100 Million ATM Program Established
iBio entered into an At-The-Market (ATM) offering agreement with Jefferies LLC, allowing the company to sell up to $100,000,000 of common stock from time to time. This program is enabled by a concurrently filed S-3 registration statement.
-
Prior ATM Program Terminated
The company terminated its previous ATM agreement, dated July 3, 2024, which had a maximum offering price of $7,350,000.
-
Significant Potential Dilution
The new ATM program's maximum value of $100 million exceeds the company's current market capitalization, indicating a substantial potential for dilution if fully utilized.
-
Enhanced Financial Flexibility
This new capital raising facility provides iBio with significant long-term funding flexibility, building on recent financings that resolved going concern doubts and extended the cash runway.
Analysis · IBIO · Life Sciences
This filing announces a significant capital raising mechanism for iBio, establishing an At-The-Market (ATM) program that allows the company to sell up to $100 million in common stock over time. This new facility is substantially larger than the company's current market capitalization and replaces a previous, smaller ATM program. While providing crucial long-term funding flexibility and extending the company's cash runway well beyond the previously reported Q3 FY28, it also introduces a substantial potential for dilution for existing shareholders if fully utilized. This move follows recent financings totaling $76 million that resolved the company's going concern doubt, indicating a proactive strategy to secure future liquidity. Investors should monitor the pace and pricing of any sales under this program.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 36.1% of the 1753 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IBIO was trading at $2.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $97.4M. The 52-week trading range was $0.56 to $6.89. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.